Modern drug discovery and development require the training of scientists who understand the molecular, physiological and quantitative basis of drug action and specificity, and who can apply modern technologies and concepts to the development of novel therapeutic strategies. This multidisciplinary doctoral training program in the Pharmacological Sciences is designed to help meet that demand by preparing students for biomedical research careers in schools of medicine, dentistry and pharmacy, in research institutes, and in governmental or industrial laboratories. The most important component of training is laboratory research, first as a series of research rotations, then in the dissertation laboratory. This training is complemented by a core course that integrates the theoretical and experimental foundations of modern biological sciences;core courses in pharmacology that emphasize quantitative analysis of drug action, pharmacokinetics, drug disposition, biostatistics and experimental design;advanced courses in specialty areas;seminar courses and journal clubs. Emphasis throughout is placed on development and refinement of communication and analytical skills. The 48 training faculty represent 17 basic science and clinical departments at Emory providing a wealth of diverse research training opportunities. Research foci in the program include Neurological Diseases and Therapy, Cancer Pharmacology, Cardiovascular Pharmacology, Chemical Biology and Drug Discovery and Novel Therapeutic Modalities. Cell Signaling, Systems and Integrative Pharmacology, and Toxicology are crosscutting themes. This Program currently supports six students each year, who are selected mainly from a pool of approximately 20-30 eligible students in the first three years of the Molecular and Systems Pharmacology (MSP) Program. Six slots are requested in this renewal. Graduates will have acquired broad familiarity with pharmacology, knowledge in depth in the area of dissertation research, and the technical, communicative and analytical skills necessary to pursue an independent research career. Students graduate an average of 5.9 years after matriculation. The research conducted by the trainees in this program will advance our knowledge of disease processes and contribute to development of novel and improved therapeutic strategies that will benefit the health of our citizens. By preparing young scientists to contribute to and lead the nation's efforts in these areas, this training program will help to ensure that our ability to imprve the nation's health remains strong in the future.

Public Health Relevance

This application requests funds to support the training of 6 graduate students per year in an interdisciplinary Pharmacological sciences graduate program. Forty-eight training faculty from 17 departments provide a wealth of diverse research training opportunities for students. The goal is to produce broadly trained scientists who will contribute t the discovery and development of novel therapeutic agents that will improve healthcare in the United States and worldwide.

Agency
National Institute of Health (NIH)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008602-18
Application #
8668965
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Emory University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Havel, J J; Li, Z; Cheng, D et al. (2015) Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. Oncogene 34:1487-98
Swanson, Andrew M; Allen, Amanda G; Shapiro, Lauren P et al. (2015) GABAA?1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection. Neuropsychopharmacology 40:1027-36
Zakas, P M; Vanijcharoenkarn, K; Markovitz, R C et al. (2015) Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors. J Thromb Haemost 13:72-81
Sanabria-Figueroa, Eduardo; Donnelly, Siobhan M; Foy, Kevin C et al. (2015) Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1. Mol Pharmacol 87:150-61
Shan, Changliang; Elf, Shannon; Ji, Quanjiang et al. (2014) Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Mol Cell 55:552-65
Taylor, Tonya N; Alter, Shawn P; Wang, Minzheng et al. (2014) Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76 Pt A:97-105
Fan, Jun; Shan, Changliang; Kang, Hee-Bum et al. (2014) Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell 53:534-48
Hudson, William H; Ortlund, Eric A (2014) The structure, function and evolution of proteins that bind DNA and RNA. Nat Rev Mol Cell Biol 15:749-60
Porter, Kristi M; Kang, Bum-Yong; Adesina, Sherry E et al. (2014) Chronic hypoxia promotes pulmonary artery endothelial cell proliferation through H2O2-induced 5-lipoxygenase. PLoS One 9:e98532
Fan, Jun; Kang, Hee-Bum; Shan, Changliang et al. (2014) Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect. J Biol Chem 289:26533-41

Showing the most recent 10 out of 57 publications